Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Achillion Pharma Takeout Less Likely Following Subpar Hep C Drug Results

thestreet.com — BOSTON (TheStreet) -- Sorry to play the Scrooge in front of Christmas, but the data released Monday on Achillion Pharmaceuticals' hepatitis C "nuc" ACH-3422 falls short of spectacular. Tamp down your hopes and dreams if you were expecting Achillion to be the next hepatitis C buyout candidate.

Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market

thestreet.com — BOSTON ( TheStreet) -- The exclusive hepatitis C pharmacy deal struck between Express Scripts and AbbVie is a serious, perhaps permanent, blow to the multi-year biotech stock bull market. The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers.

Bristol-Myers Deal Gives ImClone Execs a Big Payday

thestreet.com — The biggest winners in Wednesday's $2 billion deal between Bristol-Myers Squibb and ImClone might just be ImClone's top executives. ImClone's CEO Sam Waksal and his brother and COO Harlan Waksal will reap tens of millions of dollars from the Bristol-Myers deal, thanks to sweetheart loans from their company enabling them to exercise stock options in July for shares they can now sell at a huge premium.

Biopure Gets SEC Wells Notice

thestreet.com — Updated from 7:32 a.m. EST This is a bonus story from Adam Feuerstein, whose biotech coverage usually runs only on RealMoney. We're offering it today to TheStreet.com readers. To read Adam's commentary every day, click here for information on a free trial to RealMoney.

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

thestreet.com — BOSTON ( TheStreet) -- It's report card time. I've been going back over a year's worth of biotech columns to assess my hits and misses for 2014. Contradicting my reputation as a single-minded biotech stock "basher," I did well with bullish calls this year.

The Winners for Best and Worst Biotech CEOs of 2014 Are...

thestreet.com — BOSTON ( TheStreet) -- The votes for Best and Worst Biotech CEOs of 2014 are counted. Your chosen selections are... Best Biotech CEOs: Congrats, guys, congrats. Applause! Applause! Schenkein and Leschly (or as I like to refer to them David Leschly and Nick Schenkein) took this year's top honor in runaway style, garnering more than half your votes.

Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...

thestreet.com — BOSTON ( TheStreet) -- Ready for some fun? Here are the nominees for Worst Biotech CEO of 2014: Marc Beer of Aegerion Pharmaceuticals , John Johnson of Dendreon , co-nominees Steve Kriegsman of CytRx and Mark Ahn of , Joe Podolski of Repros Theraeutics , Linda Powers of Northwest Biotherapeutics , and last but not least, Martin Shkreli of Retrophin .

Adam on Biotech Stocks

tumblr.com — Here comes Orexigen Therapeutics, winning big-time market share from obesity pill rivals Vivus and Arena Pharmaceuticals. The chart and graph above were tweeted out this morning by professional money manager @zbiotech, who tracks new prescriptions of obesity pills using data generated by Symphony Health. For the week ended Dec.

Article Page | TheStreet

thestreet.mobi — By Adam Feuerstein - 12/12/14 - 6:05 AM EST BOSTON ( TheStreet) -- I'm really excited to bring you the nominees for the Best Biotech CEO of 2014 award. I usually write an introduction discussing how I came to choose this year's finalists, but let's skip THAT this year.

The Nominees for Best Biotechnology Co. CEO of 2014 Are...

thestreet.com — BOSTON ( TheStreet) -- I'm really excited to bring you the nominees for the Best Biotech CEO of 2014 award. I usually write an introduction discussing how I came to choose this year's finalists, but let's skip THAT this year. The incredible achievements of the CEOs below speak for themselves.
More Articles →
Dec 22, 2014

Now would be a good time for $GILD to use its cash to buy $BMY.

Dec 22, 2014

I really do want to continue the discussion about the sucky Homeland season finale. Maybe tomorrow when everything calms down.

Dec 22, 2014

$ACHN Takeout Less Likely Following Subpar Hep C Drug Results thestreet.com/story/12993244… I'm Scroogy today.

Dec 22, 2014

RT @LKulikowski: AbbVie's Exclusive Hepatitis C Deal With Express Scripts: What Wall Street's Saying lnkd.in/daqncgD

Dec 22, 2014

RT @shaneblackmon: $ESRX CNBC Question: Are you looking to do across other therapeutic areas? CEO says, "Yes..."

Dec 22, 2014

RBC buyside survey on implications of $ESRX $ABBV. The “All is well” argument for why HepC is exception, not rule. pic.twitter.com/afXBy1VYew

Dec 22, 2014

RT @ArmstrongDrew: I remember conversation w/ @MarkSchoenebaum last winter about this -- said big-picture price concern was biggest L-T risk to bio sector

Dec 22, 2014

. @FrankLasCPA @Frank_S_David @matthewherper Health plans benefit from PBM actions. Change requires revolt from doctors and patients.

Dec 22, 2014

RT @ArmstrongDrew: Here's where, a year ago, $ESRX promised a price war in hep C against $GILD: bloom.bg/1jKaz4e (Note: not a lot of people believed it)

Dec 22, 2014

RT @bradloncar: New blog post: My thoughts about a ridiculous take on biotech social media. loncarblog.com/biotech-social…

Learn how to connect with Adam on social media by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile